title: Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
abstract: OBJECTIVE
  Ixabepilone is a microtubule-stabilizing agent with activity in adult solid tumors and in pediatric tumor xenograft models that are resistant to paclitaxel. The maximum tolerated dose on the daily-for-5-days i.v. schedule was 6 mg/m(2)/dose in adults and 8 mg/m(2)/dose in children, and the primary dose-limiting toxicity (DLT) was neutropenia. This study aimed to determine the response rate to ixabepilone in six solid tumor strata in children and young adults.
  
  
  METHODS
  We conducted a phase II trial of ixabepilone (8 mg/m(2)/dose for 5 days every 21 days) using a two-stage design in taxane-naïve children and young adults with treatment-refractory, measurable rhabdomyosarcoma, Ewing sarcoma family tumors, osteosarcoma, synovial sarcoma, or malignant peripheral nerve sheath tumor, neuroblastoma, and Wilms tumor.
  
  
  RESULTS
  Sixty-one eligible patients (36 male) were enrolled. Median (range) age was 13 years (range, 3-36). Fifty-nine patients were fully evaluable for toxicity and response. DLTs, most commonly myelosuppression, occurred in 11 patients (15% incidence in 3-18 years old and 33% in 19-36 years old; P = 0.2) during cycle 1. The median (range) number of cycles was 2 (range, 1-38). No partial or complete responses (response evaluation criteria in solid tumors) were observed. Seven patients received >or=3 cycles, and two had prolonged stable disease (Wilms' tumor, 38 cycles; synovial sarcoma, 8 cycles).
  
  
  CONCLUSIONS
  Ixabepilone at 8 mg/m(2)/dose daily for 5 days was tolerable in children and adolescents, but did not show evidence of clinical activity in the childhood solid tumors studied.
authors.affiliation: Children's National Medical Center, Washington, District of Columbia 20020, USA. jacobss@cnmc.org
authors.forename: Shana
authors.initials: S
authors.lastname: Jacobs
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fox
authors.forename: Mark
authors.initials: M
authors.lastname: Krailo
authors.forename: Gwen
authors.initials: G
authors.lastname: Hartley
authors.forename: Fariba
authors.initials: F
authors.lastname: Navid
authors.forename: Leonard
authors.initials: L
authors.lastname: Wexler
authors.forename: Susan M
authors.initials: SM
authors.lastname: Blaney
authors.forename: Anne
authors.initials: A
authors.lastname: Goodwin
authors.forename: Wendy
authors.initials: W
authors.lastname: Goodspeed
authors.forename: Frank M
authors.initials: FM
authors.lastname: Balis
authors.forename: Peter C
authors.initials: PC
authors.lastname: Adamson
authors.forename: Brigitte C
authors.initials: BC
authors.lastname: Widemann
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D034261:Epothilones / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D034261:Epothilones; C430592:ixabepilone